Cochrane · systematic review · CD008642
Chinese herbal medicine for atopic eczema
Gu, S, Yang, AWH, Xue, CCL, et al. · Cochrane Database of Systematic Reviews · 2013 · Cochrane Library
SkinAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
17
current version
GRADE rated
17
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 3 · 17.6%Low 13 · 76.5%Moderate 1 · 5.9%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
CHM compared to placebo
Population: Participants with atopic eczema
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Total effectiveness rate (Analysis 1.1) Clinician's rating CHM vs placebo | RR 2.09 [1.32, 3.32] | 2 studies · 85 participants | Low Downgraded: risk of bias, inconsistency |
Itching VAS (Analysis 1.2) Participant's rating. Scale from 1 to 10 CHM vs placebo | no estimate extracted | 2 studies · 94 participants | Low Downgraded: risk of bias, inconsistency |
Overall severity score (Analysis 1.3) Clinician's rating. Scale from 1 to 80 CHM vs placebo | no estimate extracted | 4 studies · 239 participants | Very low Downgraded: risk of bias, inconsistency |
QoL (Analysis 1.5) Participant's rating. Scale from 0 to 30 CHM vs placebo | no estimate extracted | 1 study · 85 participants | Moderate Downgraded: risk of bias, inconsistency |
Adverse events (Analysis 1.7) Participant's report CHM vs placebo | RR 0.71 [0.06, 8.67] | 2 studies · 129 participants | Low Downgraded: risk of bias, inconsistency |
CHM compared to drugs
Population: Participants with atopic eczema
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Total effectiveness rate (Analysis 2.1) Clinician's rating CHM vs drugs | RR 1.43 [1.27, 1.61] | 21 studies · 1868 participants | Very low Downgraded: risk of bias, inconsistency |
Total effectiveness rate with subgroup analysis ‐ individualised treatment Clinician's rating CHM vs drugs | RR 1.5 [1.3, 1.74] | 7 studies · 567 participants | Low Downgraded: risk of bias, inconsistency |
Total effectiveness rate with subgroup analysis ‐ non‐individualised treatment Clinician's rating CHM vs drugs | RR 1.37 [1.17, 1.6] | 14 studies · 1301 participants | Very low Downgraded: risk of bias, inconsistency |
Itching VAS (Analysis 2.3) Participant's rating. Scale from 0 to 10 CHM vs drugs | no estimate extracted | 7 studies · 465 participants | Low Downgraded: risk of bias, inconsistency |
Overall severity score (Analysis 2.4) Clinician's rating. Scale from 0 to 103 CHM vs drugs | no estimate extracted | 15 studies · 1062 participants | Low Downgraded: risk of bias, inconsistency |
Adverse events (Analysis 2.6) Participant's reports CHM vs drugs | RR 0.44 [0.32, 0.61] | 15 studies · 1396 participants | Low Downgraded: risk of bias, inconsistency |
Combination of oral and topical CHM compared to same oral CHM
Population: Participants with atopic eczema
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Total effectiveness rate (Analysis 3.1) Clinician's rating Combination of oral and topical CHM vs same oral CHM | RR 1.13 [0.78, 1.63] | 1 study · 20 participants | Low Downgraded: risk of bias |
Overall severity score (Analysis 3.5) Clinician's rating. Scale from 0 to 103 Combination of oral and topical CHM vs same oral CHM | no estimate extracted | 1 study · 20 participants | Low Downgraded: risk of bias |
QoL (Analysis 3.6) Participant's rating. Scale from 0 to 30 Combination of oral and topical CHM vs same oral CHM | no estimate extracted | 1 study · 20 participants | Low Downgraded: risk of bias |
Adverse events (Analysis 3.7) Participant's report Combination of oral and topical CHM vs same oral CHM | RR 1 [0.07, 13.87] | 1 study · 20 participants | Low Downgraded: risk of bias |
Itching VAS (Analysis 3.3) Participant's rating. Scale from 0 to 10 Combination of oral and topical CHM vs same oral CHM | no estimate extracted | 1 study · 22 participants | Low Downgraded: risk of bias |
Skin lesion score (Analysis 3.4) Clinician's rating. Scale from 0 to 24 Combination of oral and topical CHM vs same oral CHM | no estimate extracted | 1 study · 22 participants | Low Downgraded: risk of bias |